Clinical Trials - DataSource by Daiichi Sankyo

A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

This study will evaluate the safety and effectiveness of mirogabalin in adult patients with diabetic peripheral neuropathic pain (DPNP) in real-world clinical practice setting in China.

CONDITIONS

Diabetic Peripheral Neuropathic Pain

PRODUCT

Other/Multi

GENDER

ALL

AGE

18 Years

SPONSOR

Daiichi Sankyo

COLLABORATOR

TRIAL RUNS IN

30 Global Locations

Trial Summary

Mirogabalin has been approved in China for the treatment of DPNP. Although there is evidence of the safety and efficacy of mirogabalin, there is a lack of real-world evidence on its safety and effectiveness to inform decision-making among a more diverse patient population in real-world clinical practice, such as patients with moderate or severe renal impairment; patients with more complications, comorbidities, and treatments; and patients with different severity of pain. This study aims to collect safety and effectiveness data to guide physicians in the clinical use of mirogabalin for the treatment of patients with DPNP in the real-world clinical practice setting.

A Prospective, Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

Patients must meet all the following criteria to be eligible for this study.1. Age ≥ 18 years at the time of informed consent form (ICF) signed.2. Patients diagnosed with DPNP (defined as patients diagnosed with type 1 or type 2 diabetes and painful distal symmetric polyneuropathy).3. Patients with a pain scale of visual analog scale (VAS( ≥ 40 mm on the day of ICF signed.4. Patients who are mirogabalin naïve prior to ICF signed and planned to initiate mirogabalin treatment.5. Patients who are able to give signed ICF for study participation and willing to provide access to previous and future medical information.Patients who meet any of the following criteria will be excluded from this study.1. Patients who have other severe pain unrelated to DPN at baseline, which may confound the assessment of DPNP.2. Patients who previously received pregabalin ≥ 300 mg/day or gabapentin ≥ 1200 mg/day to treat DPNP and declared lack of effectiveness.3. Patients who received pregabalin, gabapentin, crisugabalin, or any other DPNP analgesic medications\
within 7 days prior to ICF signed. \
Other DPNP analgesic medication includes TCAs (amitriptyline, nortriptyline), SNRIs (duloxetine, venlafaxine), antiepileptics (carbamazepine), opioids (tapentadol, tramadol).4. Patients with major psychiatric disorders (depression, Alzheimer disease, Parkinson disease, mania, bipolar disorder, psychosis, or schizophrenia, etc.) at baseline.5. Patients with contraindications for mirogabalin treatment according to China package insert of mirogabalin.6. Patients with simultaneous participation in any interventional clinical study.7. Female patients at the status of pregnancy, potential pregnancy, or breast feeding.8. Patients who have been judged by the investigator to be unsuitable to participate in the study.

This was last updated on 2025-11-06 19:34:46.079.

The content contained is taken is taken directly from public registry ClinicalTrials.gov and has not been edited.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.